Investigational Drug Details
| Drug ID: | D394 |
| Drug Name: | Lopinavir |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB01601 |
| DrugBank Description: | Lopinavir is an antiretroviral belonging to the _protease inhibitor_ class. It is marketed by Abbott as Kaletra, a co-formulation with a sub-therapeutic dose of ritonavir, as a component of combination therapy to treat HIV/AIDS. |
| PubChem ID: | 92727 |
| CasNo: | 192725-17-0 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1 |
| Structure: |
|
| InChiKey: | KJHKTHWMRKYKJE-SUGCFTRWSA-N |
| Molecular Weight: | 628.8008 |
| DrugBank Targets: | Human immunodeficiency virus type 1 protease |
| DrugBank MoA: | Lopinavir inhibits the HIV viral protease enzyme. This prevents cleavage of the gag-pol polyprotein and, therefore, improper viral assembly results. This subsequently results in non-infectious, immature viral particles. |
| DrugBank Pharmacology: | This drug is a protease inhibitor. Inhibiting HIV-1 protease (responsible for protein cleavage), results in selectively inhibiting the cleavage of HIV gag and gag-pol polyproteins, thereby preventing viral maturation. |
| DrugBank Indication: | Indicated in combination with other antiretroviral agents for the treatment of HIV-infection. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|